22nd Century Group Files FDA Renewal for VLN Reduced Nicotine Cigarettes

Reuters01-06
<a href="https://laohu8.com/S/XXII">22nd Century</a> Group Files FDA Renewal for VLN Reduced Nicotine Cigarettes

22nd Century Group Inc. has filed a renewal application with the U.S. Food and Drug Administration (FDA) for its Modified Risk Tobacco Product (MRTP) authorization for VLN® reduced nicotine content products. VLN® remains the first and only combustible cigarette authorized by the FDA specifically to help smokers reduce the health harms of smoking by lowering nicotine intake. The renewal supports the company's ongoing research and development into reduced nicotine content tobacco and the introduction of additional VLN®-based products. The FDA's original MRTP authorization for VLN® cigarettes was recognized as an innovative step in reducing smoking-related health risks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 22nd Century Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620253-en) on January 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment